Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2025 06:48 ET | Source: Research and Markets

Antibody Conjugate Oligonucleotide Market Analysis and Forecast, 2025-2035: CRISPR/Cas9 Integration with Oligonucleotide Conjugates Opens New Avenues in Gene Therapy

Dublin, May 14, 2025 (GLOBE NEWSWIRE) -- The "Antibody Conjugate Oligonucleotide Market - A Global and Regional Analysis: Focus on Type, Oligonucleotide Type, Target Disease, and Country Analysis -...
April 25, 2025 04:23 ET | Source: Research and Markets

Antibody Drug Conjugates Market and Forecast to 2030: Trends, Developments and Shares by Type of ADC, Application, Region and Company

Dublin, April 25, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...
April 18, 2025 10:21 ET | Source: Research and Markets

Antibody-drug Conjugates Innovations Research Report 2025: $227 Billion in Deals Signal ADC Market Boom - Pfizer and Daiichi Sankyo Emerge as Leading Trial Sponsors

Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: Antibody-drug conjugates" has been added to ResearchAndMarkets.com's offering. ntibody-drug conjugates (ADCs) are redefining...
April 15, 2025 17:27 ET | Source: Radiance BioPharma

Radiance Announces First Patient Dosing in Phase 1 Clinical Trial of its Next Generation ROR-1 Targeted ADC for Hematologic and Solid Malignancies

BOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjugates (‘ADCs’), today...
April 01, 2025 11:01 ET | Source: Radiance BioPharma

REPEAT -- Radiance Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of RB-164™, an ROR-1 Targeted ADC, for Hematologic and Solid Malignancies

BOSTON, Mass, April 01, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjugates (‘ADCs’), today...
March 24, 2025 10:13 ET | Source: Research and Markets

Antibody Drug Conjugate (ADC) Market Research 2024-2035: Currently, 47% of the ADCs are in Discovery / Preclinical Stages of Development

Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target...
March 24, 2025 06:08 ET | Source: Research and Markets

Bispecific Antibody Drug Conjugates (BsADCs) Market Outlook 2024-2029: Additional Candidates Undergo Clinical Studies and Become Commercially Available

Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Global Bispecific Antibody Drug Conjugates Research Outlook 2029" report has been added to ResearchAndMarkets.com's offering. Bispecific antibody...
March 24, 2025 05:01 ET | Source: Research and Markets

Global Cancer Antibody Drug Conjugates Market Landscape 2024-2030 Featuring Biocytogen, Merck, AstraZeneca, Pfizer, Daiichi Sankyo, and ADC Therapeutics

Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ...
March 19, 2025 07:26 ET | Source: Research and Markets

Antibody Drug Conjugates (ADCs) Contract Manufacturing Market Research Report 2025: Growth Trends and Regional Forecasts to 2030 with Details on Segmental and Player Shares

Dublin, March 19, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report by Linker (Cleavable, Non-Cleavable), Condition...
March 04, 2025 07:34 ET | Source: Research and Markets

AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)

Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "AXL Inhibitors - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...

Next Page keyboard_arrow_right